Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Nov 5, 2025
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial
Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026
Read more at globenewswire.com
